| Papzimeos™ (Zopapogene Imadenovec-Drba) | 2026D0141B · Effective Apr 1, 2026 · Commercial | 1 | Original policy ↗ |
| Parsabiv® (Etelcalcetide) | 2026D0075J · Effective Apr 1, 2026 · Commercial | 1 | Original policy ↗ |
| Pediatric and Neonatal Critical and Intensive Care Services Policy, Professional | Commercial | 4 | Original policy ↗ |
| Peoples Health Plans prior authorization requirements | Effective May 1, 2026 · Medicaid | 1,538 | Original policy ↗ |
| Percutaneous Coronary Interventions | MMP235.16 · Effective Oct 1, 2026 | 19 | Original policy ↗ |
| Percutaneous Neuroablation for Pancreatic Cancer Pain, Severe Cancer Pain, and Trigeminal Neuralgia – Commercial and Individual Exchange Medical Policy | 2026T0629J · Commercial | 5 | Original policy ↗ |
| Percutaneous Patent Foramen Ovale (PFO) Closure | 2026T0606J · Effective Jan 1, 2026 · Commercial | 1 | Original policy ↗ |
| Percutaneous Ventricular Assist Device | MMP240.18 · Effective Oct 1, 2026 | 3 | Original policy ↗ |
| Percutaneous Vertebroplasty and Kyphoplasty | 2026T0581Q · Effective Mar 1, 2026 · Commercial | 6 | Original policy ↗ |
| Pharmacogenetic Panel Testing | 2026T0587Z · Effective Oct 1, 2026 · Commercial | 23 | Original policy ↗ |
| Pharmacogenomics Testing | MMP391.17 · Effective Sep 1, 2026 | 9 | Original policy ↗ |
| Physical Medicine & Rehabilitation: Maximum Combined Frequency per Day Policy, Professional | Commercial | 26 | Original policy ↗ |
| Physical Medicine & Rehabilitation: PT, OT and Evaluation & Management Policy, Professional | 2026R0098A · Commercial | 4 | Original policy ↗ |
| Plagiocephaly and Craniosynostosis Treatment | 2026T0031GG · Effective Jan 1, 2026 · Commercial | 5 | Original policy ↗ |
| Platelet Rich Plasma Therapies | MMP392.05 · Effective Sep 1, 2026 | 4 | Original policy ↗ |
| Pneumatic Compression Devices | 2026T0563X · Effective Jun 1, 2026 · Commercial | 19 | Original policy ↗ |
| Positron Emission Tomography Scan for Myocardial Imaging | MMP242.21 · Effective Oct 1, 2026 | 9 | Original policy ↗ |
| Preimplantation Genetic Testing and Related Services | 2026T0597Q · Effective May 1, 2026 · Commercial | 35 | Original policy ↗ |
| Preventive Care Services | MP.016.60 · Effective Oct 1, 2026 · Commercial | 403 | Original policy ↗ |
| Preventive Medicine and Screening Policy, Professional | 2026R0013C · Commercial | 92 | Original policy ↗ |
| Preventive Vaccines (Immunizations) | 2025D0031T · Effective Dec 1, 2025 · Commercial | — | Original policy ↗ |
| Prior Authorization Requirements for UnitedHealthcare | Effective Jan 1, 2026 · Commercial | 2,174 | Original policy ↗ |
| Prior authorization requirements for UnitedHealthcare Complete | Effective Jan 1, 2026 · Commercial | 3,105 | Original policy ↗ |
| Prior authorization requirements for UnitedHealthcare Complete | Effective May 1, 2026 · Commercial | 2,151 | Original policy ↗ |
| Private Duty Nursing Services | MP.017.22 · Effective Aug 1, 2026 · Commercial | 1 | Original policy ↗ |
| Procedure and Place of Service Policy, Professional | Commercial | 1 | Original policy ↗ |
| Procedure to Modifier Policy, Professional | Effective Jul 1, 2020 · Commercial | 1 | Original policy ↗ |
| Professional/Technical Component Policy, Professional | Commercial | 38 | Original policy ↗ |
| Prolotherapy and Platelet Rich Plasma Therapies | 2026T0498CC · Effective Jan 1, 2026 · Commercial | 5 | Original policy ↗ |
| Prostate Biopsy Specimen Analysis Policy, Professional and Facility | 2026R8015A · Effective Aug 26, 2026 · Commercial | 2 | Original policy ↗ |
| Prostate Services and Procedures and Impotence Treatment | MMP075.14 · Effective Sep 1, 2026 | 7 | Original policy ↗ |
| Prostate Surgeries and Interventions | 2026T0618P · Effective Jun 1, 2026 · Commercial | 24 | Original policy ↗ |
| Proton Beam Radiation Therapy | 2026T0132MM · Effective Mar 1, 2026 · Commercial | 7 | Original policy ↗ |
| Provider Administered Drugs – Preferred Products | 2026D0112E · Effective Jul 1, 2026 · Commercial | 1 | Original policy ↗ |
| Provider Administered Drugs – Site of Care – Commercial Medical Benefit Drug Policy | 2026D0121X · Effective Oct 1, 2026 · Commercial | — | Original policy ↗ |
| Qalsody® (Tofersen) | 2026D0123F · Effective May 1, 2026 · Commercial | 1 | Original policy ↗ |
| Radiation and Oncologic Procedures | MMP077.17 · Effective Sep 1, 2026 | 20 | Original policy ↗ |
| Radiation Therapy: Fractionation, Image-Guidance, and Special Services | 2026T0613L · Effective Mar 1, 2026 · Commercial | 18 | Original policy ↗ |
| Radiologic Diagnostic Procedures | MMP076.18 · Effective Sep 1, 2026 | 52 | Original policy ↗ |
| Reblozyl® (Luspatercept-Aamt) | 2026D0084L · Effective Aug 1, 2026 · Commercial | 1 | Original policy ↗ |
| Rebyota® (Fecal Microbiota, Live-Jslm) | 2025D0124D · Effective Dec 1, 2025 · Commercial | 1 | Original policy ↗ |
| Replacement Codes Policy, Professional | 2026R0128A · Commercial | 40 | Original policy ↗ |
| Repository Corticotropin Injections | 2026D0037V · Effective Apr 1, 2026 · Commercial | 2 | Original policy ↗ |
| Respiratory Interleukin-5 Inhibitor | 2026D0055AA · Effective Oct 1, 2026 · Commercial | 4 | Original policy ↗ |
| Respiratory Pathogen Nucleic Acid Detection Testing | 2026T0661F · Effective Oct 1, 2026 · Commercial | 8 | Original policy ↗ |
| Review at Launch for New to Market Medications | 2025D0060K · Effective Dec 1, 2025 · Commercial | 3 | Original policy ↗ |
| Rhinoplasty and Other Nasal Procedures | MP.019.34 · Effective Apr 1, 2026 · Commercial | 18 | Original policy ↗ |
| Rituximab (Riabni®, Rituxan®, Ruxience®, & Truxima®) | 2026D0003AO · Effective Jan 1, 2026 · Commercial | 8 | Original policy ↗ |
| RNA-Targeted Therapies (Amvuttra® and Onpattro®) | 2026D0072O · Effective Jun 1, 2026 · Commercial | 2 | Original policy ↗ |
| Roctavian® (Valoctocogene Roxaparvovec-Rvox) – Commercial Medical Benefit Drug Policy | 2026D0094F · Effective Jan 1, 2026 · Commercial | 1 | Original policy ↗ |
